WP
ZNTL icon

Woodline Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Woodline Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-266,032
Closed -$623K – 1164
2026
Q1 		$623K Sell
266,032
-264,550
-50% -$683K ﹤0.01% 938
2025
Q4 		$716K Hold
530,582
– – ﹤0.01% 868
2025
Q3 		$801K Hold
530,582
– – ﹤0.01% 813
2025
Q2 		$615K Hold
530,582
– – ﹤0.01% 839
2025
Q1 		$844K Hold
530,582
– – 0.01% 781
2024
Q4 		$1.61M Sell
530,582
-524,700
-50% -$1.72M 0.01% 689
2024
Q3 		$3.88M Sell
1,055,282
-461,795
-30% -$1.68M 0.03% 417
2024
Q2 		$6.2M Buy
1,517,077
+80,051
+6% +$894K 0.06% 315
2024
Q1 		$22.6M Buy
1,437,026
+33,473
+2% +$460K 0.21% 150
2023
Q4 		$21.3M Buy
1,403,553
+403,553
+40% +$5.89M 0.23% 130
2023
Q3 		$20.1M Sell
1,000,000
-94,974
-9% -$2.41M 0.24% 129
2023
Q2 		$30.9M Sell
1,094,974
-1,070,577
-49% -$25.7M 0.37% 75
2023
Q1 		$37.2M Buy
2,165,551
+2,019,032
+1,378% +$40.9M 0.51% 46
2022
Q4 		$2.95M Sell
146,519
-173,228
-54% -$3.73M 0.04% 419
2022
Q3 		$6.93M Buy
319,747
+138,475
+76% +$3.79M 0.1% 246
2022
Q2 		$5.09M Buy
181,272
+140,524
+345% +$3.72M 0.08% 259
2022
Q1 		$1.88M Sell
40,748
-327,425
-89% -$17.7M 0.03% 400
2021
Q4 		$30.9M Sell
368,173
-139,674
-28% -$10.8M 0.44% 49
2021
Q3 		$33.8M Buy
507,847
+2,172
+0.4% +$125K 0.55% 43
2021
Q2 		$26.9M Buy
505,675
+361,514
+251% +$19.4M 0.5% 50
2021
Q1 		$6.25M Buy
144,161
+4,161
+3% +$179K 0.14% 170
2020
Q4 		$7.27M Buy
140,000
+2,116
+2% +$95.4K 0.19% 138
2020
Q3 		$4.51M Buy
137,884
+94,158
+215% +$3.3M 0.15% 135
2020
Q2 		$2.1M Buy
+43,726
New +$1.68M 0.08% 133

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Woodline Partners's ZNTL Position: Q2 2026 in Review

Woodline Partners sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 266,032 shares — an estimated $623K sold.

Woodline Partners first reported a position in ZNTL in Q2 2020 and held it in 24 quarters. The position peaked at $37.2M in Q1 2023. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Woodline Partners reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 266,032 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $623K.
  • Woodline Partners first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 24 quarters.
  • Woodline Partners's Zentalis Pharmaceuticals position peaked at $37.2M in Q1 2023.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.